
    
      Phase I study conducted in participants whose tumors express the target of interest.
      Pharmacokinetics (PK), pharmacodynamics (PD), biomarkers will be determined to support dose
      selection.

      Phase II study conducted in Cutaneous T-cell lymphoma (CTCL) participants who are CD70
      positive. PK, PD, biomarkers and immunohistochemistry (IHC) will be determined to assess
      efficacy.
    
  